Doxofylline

From Wikipedia, the free encyclopedia

Template:Short description Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Doxofylline
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		By mouth
ATC codePage Template:Plainlist/styles.css has no content.
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
  • In general: ℞ (Prescription only)
Identifiers
  • 7-(1,3-Dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC11H14N4O4
Molar mass266.257 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
  • CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3
  • InChI=1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3
  • Key:HWXIGFIVGWUZAO-UHFFFAOYSA-N
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content.  (verify)

Doxofylline (also known as doxophylline) is a phosphodiesterase inhibiting bronchodilator used in the treatment of chronic respiratory diseases such as asthma[1] and COPD.[2] Like theophylline, it is a xanthine derivative.[3][4]

Medical uses

Doxophylline is used to treat chronic respiratory diseases such as asthma[1] and COPD.[2] in clinical studies, it appears to be equal in efficacy to theophylline but with significantly fewer side effects.[5] In 2014, the US Food and Drug Administration (FDA) granted an orphan drug designation to doxofylline for the treatment of bronchiectasis following the submission of an application by Alitair Pharmaceuticals.[6][7][8]

Pharmacology

Unlike other xanthines, doxofylline lacks any significant affinity for adenosine receptors and does not produce stimulant effects. This suggests that its antiasthmatic effects are mediated by another mechanism, perhaps its actions on phosphodiesterase.[1] From a pharmacokinetic point of view, doxofylline importantly differs from theophylline also because it lacks the ability to interfere with the cytochrome enzymes CYP1A2, CYP2E1 and CYP3A4, thus preventing significant interaction with other drugs metabolized via these pathways in the liver.[9][10]

Concomitant treatment with certain other medications (including allopurinol, H2 receptor antagonists, lincosamide antibiotics, macrolide antibiotics, and propranolol) can decrease the hepatic clearance of doxofylline, which can result in increased serum levels of doxofylline.

Names

It is marketed under many brand names worldwide, including: Xiva, An Li Nuo Er, An Sai Ma, Ansimar, Asima, Bestofyline, Chuan Ning, D-Fyal, Dilatair, Doxiba, Doxiva, Doxobid, Doxobron, Doxofilina, Doxofillina, Doxofyllin, Doxoll, Doxophylline, Doxovent, Doxyjohn, Fei Te Ai Si, Fixolin, Jian Fang Neng, Lang Ming, Lv Meng, Mai Ping Xi, Maxivent, Mucosma, Na De Lai, Phylex, Phyllin, Puroxan, Rexipin, Shu Zhi, Shuai An, Shuweixin, Suo Di, Suo Ji, Suo Li An, Xi Si Nuo, Xin Qian Ping, Xin Xi Ping, Yi Suo, and Yili.[11]

It is also marketed as a combination drug with terbutaline as Doxoll-TL, Mucosma-T and Phylex-TR.[11] It is also marketed as a combination drug with montelukast as Doxoll-ML, Doxomont, Doxoril-M, Doxovent-M, Lunair-M, and Venidox-M.[11]

References

Page Template:Reflist/styles.css has no content.

  1. ^ a b c Page Module:Citation/CS1/styles.css has no content.Cirillo R, Barone D, Franzone JS (1988). "Doxofylline, an antiasthmatic drug lacking affinity for adenosine receptors". Archives Internationales de Pharmacodynamie et de Therapie. 295: 221–37. PMID 3245738.
  2. ^ a b Page Module:Citation/CS1/styles.css has no content.Cazzola M, Calzetta L, Rogliani P, Page C, Matera MG (August 2018). "Impact of doxofylline in COPD: A pairwise meta-analysis" (PDF). Pulmonary Pharmacology & Therapeutics. 51: 1–9. doi:10.1016/j.pupt.2018.04.010. PMID 29705620.
  3. ^ Page Module:Citation/CS1/styles.css has no content.Dini FL, Cogo R (2001). "Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects". Current Medical Research and Opinion. 16 (4): 258–68. doi:10.1185/030079901750120196. PMID 11268710.
  4. ^ Page Module:Citation/CS1/styles.css has no content.Poggi R, Brandolese R, Bernasconi M, Manzin E, Rossi A (October 1989). "Doxofylline and respiratory mechanics. Short-term effects in mechanically ventilated patients with airflow obstruction and respiratory failure". Chest. 96 (4): 772–8. doi:10.1378/chest.96.4.772. PMID 2791671.{{cite journal}}: CS1 maint: deprecated archival service (link)
  5. ^ Page Module:Citation/CS1/styles.css has no content.Sankar J, Lodha R, Kabra SK (2008). "Doxofylline: The next generation methylxanthine". Indian Journal of Pediatrics. 75 (3): 251–254. doi:10.1007/s12098-008-0054-1. PMID 18376093. S2CID 19283297.
  6. ^ Page Module:Citation/CS1/styles.css has no content."Orphan Drug Designations and Approvals List as of 12-01-2014" (PDF). Archived from the original (PDF) on 2018-09-16. Retrieved 2018-09-16.
  7. ^ Page Module:Citation/CS1/styles.css has no content.SMI Support. "News Release 10/26/15". www.alitair.com. Archived from the original on 2018-09-16. Retrieved 2018-09-16.
  8. ^ Page Module:Citation/CS1/styles.css has no content."Doxofylline - AdisInsight". adisinsight.springer.com. Retrieved 2018-09-16.
  9. ^ Page Module:Citation/CS1/styles.css has no content.Mennini FS, Sciattella P, Marcellusi A, Marcobelli A, Russo A, Caputi AP (October 2017). "Treatment plan comparison in acute and chronic respiratory tract diseases: an observational study of doxophylline vs. theophylline" (PDF). Expert Review of Pharmacoeconomics & Outcomes Research. 17 (5): 503–510. doi:10.1080/14737167.2017.1301815. hdl:2108/194830. PMID 28277853. S2CID 37678705.
  10. ^ Page Module:Citation/CS1/styles.css has no content.Matera MG, Page C, Cazzola M (2017-12-05). "Doxofylline is not just another theophylline!". International Journal of Chronic Obstructive Pulmonary Disease. 12: 3487–3493. doi:10.2147/COPD.S150887. PMC 5723117. PMID 29255355.
  11. ^ a b c Page Module:Citation/CS1/styles.css has no content."Doxofylline - international brand names". Drugs.com. Retrieved 18 January 2017.

Further reading

Page Template:Refbegin/styles.css has no content.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.


Template:Asbox

Retrieved from "https://cosmopedia.co/index.php?title=Doxofylline&oldid=6090856"